Analyst Price Targets — EQ
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 28, 2026 1:00 pm | — | Raymond James | $7.00 | $2.94 | TheFly | Equillium price target raised to $7 from $6 at Raymond James |
| May 28, 2026 11:22 am | Alex Thompson | Stifel Nicolaus | $5.00 | $2.63 | StreetInsider | Equillium (EQ) Stifel Reiterated at Buy by Stifel After Investor Event on AhR, miR-124 Biology |
| May 28, 2026 10:05 am | Thomas Smith | Leerink Partners | $6.00 | $2.63 | StreetInsider | Leerink Upgrades Equillium (EQ) to Outperform |
| April 23, 2026 10:32 am | — | Oppenheimer | $7.00 | $2.33 | TheFly | Equillium initiated with an Outperform at Oppenheimer |
| April 13, 2026 8:09 pm | — | Raymond James | $6.00 | $1.70 | TheFly | Equillium initiated with a Strong Buy at Raymond James |
| March 28, 2025 10:10 am | Thomas Smith | Leerink Partners | $1.00 | $0.40 | TheFly | Equillium downgraded to Market Perform from Outperform at Leerink |
Latest News for EQ
Three-year renewal follows early campaign results that delivered up to 40% increases in average order value and nearly double the conversion rates using ClearLake TORONTO, ON / ACCESS Newswire / June 18, 2026 / EQ Inc. (TSXV:EQ.V) ("EQ Works" or the "Company"), a leader in AI and data-driven software and solutions that empowers brands to better understand, acquire, and retain their most valuable customers, today…
LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June 1, 2026, the Compensation Committee of Equillium's Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 145,000 shares of common stock to a…
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript
Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship between the aryl hydrocarbon receptor, or AhR, and miR-124, a microRNA implicated in inflammatory disease biology.
LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55pm EDT.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EQ.
U.S. House Trading
No House trades found for EQ.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.